| Send E-mail to: cote_r@ccnt.usc.edu | |
| Telephone: 323-865-3270 | Fax: 323-865-0077 |
| Office: NOR 2413 | Mail Code: 9092 HSC |
Education:
BA 1976 Chemistry - University of California, Irvine
BS 1976 Biology - University of California, Irvine
MD 1980 Medicine - University of Chicago Pritzker School of Medicine
Started at USC: 1990
Research Topics: Cancer Cell Biology, Gene Regulation/Transcription, Cancer Treatment, Cell Cycle, Growth & Proliferation, Cell Death, Signal Transduction
Research Description
Dr. Cote's major areas of investigation are detection and characterization of micrometastases in patients with epithelial tumors and analysis of cellular and molecular markers of tumor progression in patients with cancer. He is focused on the study of bladder, breast, lung and prostate cancer. His work includes an examination and dissection of the relationship of cell cycle abnormalities and cancer progression, and an investigation of the clinical significance of angiogenesis in cancer prognosis.
Other major projects that he is involved in are: Analysis of tumor suppressor genes in human cancer; Molecular Mechanisms of Racial/Ethnic Variation in Prostate Cancer Risk and Mechanisms of Androgen Independence in Prostate Cancer
In addition, Dr. Cote is interested in the development and application of methods to detect occult micrometastasis in the bone marrow and lymph nodes of patients with early stage and late stage breast, lung, prostate and colon cancer using immunohistochemistry and the reverse transcription polymerase chain reaction techniques. The presence of occult metastasis may be an important means to identify patients at greatest risk for developing metastatic disease. He is also investigating methods by which the detection of occult micrometastasis can be automated using image analysis.
Dr. Cote has been involved in various collaborative works, one with Drs. Taylor and Shi, on the investigation of techniques in immunohistochemistry, particularly the antigen retrieval technology. The other is in collaboration with other researchers from USC, UC Berkeley and Oak Ridge National Laboratory, which we are developing an optomechanical chip for specific detection of molecular interactions relevant to cancer. They are expected to provide detection and quantitative analysis of molecular interaction between DNA, RNA and protein molecules in vitro. These portable microarrays will be used in cancer diagnosis and prognosis.
10 Selected Publications:
Click here to view all the publications for this faculty
Ishikawa FN,Chang HK,Curreli M,Liao HI,Olson CA,Chen PC,Zhang R,Roberts RW,Sun R,Cote RJ,Thompson ME,Zhou C - Label-Free, Electrical Detection of the SARS Virus N-Protein with Nanowire Biosensors Utilizing Antibody Mimics as Capture Probes. - ACS Nano [2009] May 7;(): PubMed
Balic M,Pichler M,Strutz J,Heitzer E,Ausch C,Samonigg H,Cote RJ,Dandachi N - High Quality Assessment of DNA Methylation in Archival Tissues from Colorectal Cancer Patients Using Quantitative High-Resolution Melting Analysis. - J Mol Diagn [2009] Feb 5;(): PubMed
Youssef RF,Mitra AP,Bartsch G Jr,Jones PA,Skinner DG,Cote RJ - Molecular targets and targeted therapies in bladder cancer management. - World J Urol [2009] Feb;27(1):9-20 PubMed
Mitra AP,Cote RJ - Molecular Pathogenesis and Diagnostics of Bladder Cancer. - Annu Rev Pathol [2008] Oct 7;(): PubMed
Pasin E,Josephson DY,Mitra AP,Cote RJ,Stein JP - Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. - Rev Urol [2008] Winter;10(1):31-43 PubMed
Shi SR,Liu C,Pootrakul L,Tang L,Young A,Chen R,Cote RJ,Taylor CR - Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry. - Am J Clin Pathol [2008] Mar;129(3):358-66 PubMed
Coté RJ - Sterilization and filtration. - Curr Protoc Cell Biol [2001] May;Chapter 1():Unit 1.4 PubMed
Coté RJ - Aseptic technique for cell culture. - Curr Protoc Cell Biol [2001] May;Chapter 1():Unit 1.3 PubMed
Birkhahn M,Mitra AP,Cote RJ - Molecular markers for bladder cancer: the road to a multimarker approach. - Expert Rev Anticancer Ther [2007] Dec;7(12):1717-27 PubMed
George B,Datar RH,Wu L,Cai J,Patten N,Beil SJ,Groshen S,Stein J,Skinner D,Jones PA,Cote RJ - p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. - J Clin Oncol [2007] Dec 1;25(34):5352-8 PubMed
|
